Giant cell arteritis (GCA) is widely classified as an autoimmune disease. It is the most common form of vasculitis in people over 50 in Western countries, and it results from the immune system attacking the walls of medium and large arteries, particularly the temporal arteries near the temples and the aorta. The underlying biology, genetic associations, and response to immune-suppressing treatments all point firmly toward autoimmunity.
Why GCA Is Considered Autoimmune
The hallmark of an autoimmune disease is the immune system mistakenly targeting the body’s own tissues. In GCA, that target is the arterial wall. Immune cells, particularly a type of white blood cell called CD4 T cells, infiltrate the artery and trigger inflammation that thickens and narrows the vessel. The inflammatory signature found in affected arteries includes a broad mix of immune signaling molecules: IL-2, interferon-gamma, IL-17, IL-21, and others. This pattern reflects widespread, dysregulated immune activation rather than a response to any known infection.
A key part of the problem appears to be a broken “braking system.” Normally, a specialized population of CD8 regulatory T cells keeps CD4 T cells in check by releasing an enzyme that dampens their activation and survival. In people with GCA, these regulatory cells are defective. Without that control mechanism, CD4 T cells expand unchecked and become hyperactive, driving the chronic arterial inflammation that defines the disease.
IL-6, a powerful inflammatory signaling molecule, plays a central role. It drives the development of Th17 cells, a subset of immune cells found both in the inflamed artery walls and at elevated levels in the bloodstream of untreated patients. IL-6 also stimulates the production of acute-phase proteins that further fuel inflammation, promote abnormal blood vessel growth in the artery wall, and encourage tissue remodeling that can permanently damage the vessel.
Genetic Risk Factors
GCA has a strong genetic component rooted in the same immune-system genes implicated in other autoimmune conditions. The most consistent genetic risk factor is a variant called HLA-DRB1*04, part of the HLA class II region. These genes control how the immune system identifies threats, and specific variations in them are linked to many autoimmune diseases, including rheumatoid arthritis and type 1 diabetes. A large-scale genetic analysis also identified associations with genes involved in immune signaling, including PTPN22 (a gene linked to multiple autoimmune conditions) and REL, which helps regulate inflammatory responses. The disease is polygenic, meaning no single gene causes it, but several together raise susceptibility.
Who Gets GCA
GCA almost exclusively affects people over age 50, with the average onset in the mid-to-late 70s. It is more common in women and in people of Northern European descent. Between 40% and 60% of GCA patients also develop polymyalgia rheumatica (PMR), a condition causing severe stiffness and aching in the shoulders, neck, and hips. The relationship runs both directions: in a large Swedish cohort of patients with confirmed PMR, about 9% were eventually diagnosed with GCA as well.
Symptoms and the Risk of Vision Loss
The most common symptoms are a new, persistent headache (often at the temples), scalp tenderness, jaw pain when chewing, and general fatigue or weight loss. Some people notice blurred vision or brief episodes where vision goes dark in one eye.
Vision loss is the most feared complication. In a study of 258 GCA patients, about 22% suffered permanent vision loss. In more than half of those cases, the damage occurred before steroids were started. Even after treatment began, 23% of patients with visual symptoms continued to lose vision, and only 5% showed improvement. This is why GCA is treated as a medical emergency when visual symptoms are present.
How GCA Is Diagnosed
Diagnosis relies on a combination of symptoms, blood tests, imaging, and sometimes a tissue sample. The 2022 classification criteria from the American College of Rheumatology and EULAR use a point-based system. A positive temporal artery biopsy or the characteristic “halo sign” on ultrasound (a dark ring around the artery indicating wall swelling) earns the highest score. Elevated inflammatory markers, sudden vision loss, and classic symptoms like jaw claudication and morning stiffness in the shoulders each contribute additional points. A cumulative score of 6 or more supports a GCA classification.
Blood tests for inflammation are a practical first step. GCA patients typically show markedly elevated levels: average ESR around 66 mm/hr and CRP around 91 mg/L, both well above normal ranges. That said, about 3% of confirmed GCA patients have completely normal inflammatory markers, so normal blood work alone does not rule it out.
Ultrasound of the temporal arteries has become a valuable non-invasive option. Compared with biopsy, ultrasound has a sensitivity of about 71% and specificity of 93%, meaning it catches most cases and rarely gives a false positive. Biopsy remains useful when ultrasound results are inconclusive, since it provides direct evidence of the immune cell infiltration in the artery wall.
Treatment: Steroids and Beyond
High-dose corticosteroids remain the first-line treatment and are started immediately when GCA is suspected, often before the diagnosis is formally confirmed. Steroids are highly effective at suppressing the key inflammatory drivers of the disease, including IL-6, IL-17, and IL-23. Most patients notice rapid improvement in symptoms within days.
The challenge is that GCA often requires months or years of steroid treatment, and long-term steroid use carries significant side effects: bone thinning, weight gain, elevated blood sugar, and increased infection risk. This has driven interest in steroid-sparing alternatives.
Tocilizumab, a medication that blocks IL-6, has emerged as the most important addition to GCA treatment. Two randomized controlled trials demonstrated that it reduces steroid exposure by at least 50%. In one study using an aggressive steroid-sparing protocol, patients received only three days of intravenous steroids at the start, then tocilizumab alone. After one year of treatment, 72% were in relapse-free remission. At four years of follow-up, 61% remained in drug-free, relapse-free remission, meaning they needed no ongoing medication at all. For many patients, tocilizumab has transformed GCA from a disease requiring years of steroids into one that can potentially be controlled with a finite course of treatment.
GCA Compared to Other Autoimmune Diseases
GCA shares core features with other autoimmune conditions: genetic predisposition through HLA genes, loss of immune self-tolerance, T cell-driven tissue damage, and responsiveness to immunosuppressive therapy. What sets it apart is its target (arteries rather than joints, nerves, or organs) and its sharp age cutoff. Unlike rheumatoid arthritis or lupus, which can appear at any adult age, GCA is essentially nonexistent before 50. This suggests that age-related changes in the immune system, particularly the declining ability of regulatory T cells to control inflammation, are a necessary ingredient on top of genetic susceptibility.
The disease also behaves somewhat differently from autoimmune conditions that follow a chronic relapsing course. A substantial portion of GCA patients achieve lasting remission after treatment, especially with tocilizumab-based regimens. Others do relapse and require longer-term management, but the trajectory is generally more favorable than many lifelong autoimmune diseases.